肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Tesaro的卵巢癌药物Zejula加入了癌症药物基金

2018-06-01 MedSci MedSci原创

卵巢癌药物Zejula
关注

Tesaro的卵巢癌药物Zejula (niraparib)被癌症药物基金(CDF)接受，它是第一个被证明对BRCA突变和无BRCA突变的患者有效的PARP抑制剂。由于尚未获得Zejula的生存数据，NICE已经通过CDF为已接受两种化疗方案的BRCA突变的妇女和未接受两种或两种以上化疗方案的无BRCA突变的妇女推荐该药物，从而进一步收集数据。"复发性卵巢癌是一种癌症形式，其治疗的一个关键目标是尽



Tesaro的卵巢癌药物Zejula (niraparib)被癌症药物基金(CDF)接受，它是第一个被证明对BRCA突变和无BRCA突变的患者有效的PARP抑制剂。

由于尚未获得Zejula的生存数据，NICE已经通过CDF为已接受两种化疗方案的BRCA突变的妇女和未接受两种或两种以上化疗方案的无BRCA突变的妇女推荐该药物，从而进一步收集数据。

"复发性卵巢癌是一种癌症形式，其治疗的一个关键目标是尽可能延长生存期，提高生活质量。" 伦敦大学癌症研究所医学肿瘤学教授Jonathan Ledermann说。Zejula提供了一个机会，可以将这种癌症推迟几个月复发或进展，在某些情况下甚至可以推迟数年。这是向前迈出的重要一步。至关重要的是，这一决定为许多妇女打开了一扇大门，她们直到现在还没有选择使用PARP抑制剂进行维持治疗。

在英国，卵巢癌是所有妇科癌症中死亡率最高的。它是欧洲发病率最高的国家之一，其生存率最低。在英国，新确诊的卵巢癌病例是每10万人中有16例，而欧洲的平均水平是每10万人中有12.6例。每年有4，100名妇女死于卵巢癌--每天有11名妇女死于卵巢癌。


此文系梅斯医学（MedSci)原创整理编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1795648, encodeId=ae121e956484e, content=<a href='/topic/show?id=50ca1e28800' target=_blank style='color:#2F92EE;'>#Tesaro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17288, encryptionId=50ca1e28800, topicName=Tesaro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Dec 31 12:49:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734741, encodeId=31291e3474165, content=<a href='/topic/show?id=4eb91901934' target=_blank style='color:#2F92EE;'>#Zejula#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19019, encryptionId=4eb91901934, topicName=Zejula)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f9c33811778, createdName=sunylz, createdTime=Fri Jan 25 07:49:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569985, encodeId=56a9156998518, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Sun Jun 03 13:49:00 CST 2018, time=2018-06-03, status=1, ipAttribution=)]
    2018-12-31 huangshifeng

    #Tesaro#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1795648, encodeId=ae121e956484e, content=<a href='/topic/show?id=50ca1e28800' target=_blank style='color:#2F92EE;'>#Tesaro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17288, encryptionId=50ca1e28800, topicName=Tesaro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Dec 31 12:49:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734741, encodeId=31291e3474165, content=<a href='/topic/show?id=4eb91901934' target=_blank style='color:#2F92EE;'>#Zejula#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19019, encryptionId=4eb91901934, topicName=Zejula)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f9c33811778, createdName=sunylz, createdTime=Fri Jan 25 07:49:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569985, encodeId=56a9156998518, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Sun Jun 03 13:49:00 CST 2018, time=2018-06-03, status=1, ipAttribution=)]
    2019-01-25 sunylz

    #Zejula#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1795648, encodeId=ae121e956484e, content=<a href='/topic/show?id=50ca1e28800' target=_blank style='color:#2F92EE;'>#Tesaro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17288, encryptionId=50ca1e28800, topicName=Tesaro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Dec 31 12:49:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734741, encodeId=31291e3474165, content=<a href='/topic/show?id=4eb91901934' target=_blank style='color:#2F92EE;'>#Zejula#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19019, encryptionId=4eb91901934, topicName=Zejula)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f9c33811778, createdName=sunylz, createdTime=Fri Jan 25 07:49:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569985, encodeId=56a9156998518, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Sun Jun 03 13:49:00 CST 2018, time=2018-06-03, status=1, ipAttribution=)]
    2018-06-03 surilei

    #癌症药物#

    0